NO20045051L - 2,5-disubstituerte 3-mercaptopentansyre - Google Patents

2,5-disubstituerte 3-mercaptopentansyre

Info

Publication number
NO20045051L
NO20045051L NO20045051A NO20045051A NO20045051L NO 20045051 L NO20045051 L NO 20045051L NO 20045051 A NO20045051 A NO 20045051A NO 20045051 A NO20045051 A NO 20045051A NO 20045051 L NO20045051 L NO 20045051L
Authority
NO
Norway
Prior art keywords
compounds
present
solvates
disubstituted
pharmaceutically acceptable
Prior art date
Application number
NO20045051A
Other languages
English (en)
Inventor
Magnus Polla
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20045051L publication Critical patent/NO20045051L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/40Unsubstituted amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Legemiddel Foreliggende oppfinnelse angår forbindelser med formel (I) og farmasøytisk akseptable salter eller solvater derav eller solvater av slike salter,. idet forbindelsene hemmer karboksypeptidase U og kan således anvendes ved forebygging og behandling av sykdommer hvor hemning av karboksypeptidase U er fordelaktig. I ytterligere aspekter, angår oppfinnelsen forbindelser ifølge foreliggende oppfinnelse for anvendelse i terapi; fremgangsmåter for fremstilling av slik nye forbindelser; farmasøytiske preparater inneholdende minst én forbindelse ifølge foreliggende oppfinnelse eller et farmasøytisk akseptabelt salt eller solvat derav, som aktiv bestanddel; og anvendelse av de aktive forbindelser ved fremstilling av medikamenter for medisinsk anvendelse angitt ovenfor.
NO20045051A 2002-06-14 2004-11-19 2,5-disubstituerte 3-mercaptopentansyre NO20045051L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201837A SE0201837D0 (sv) 2002-06-14 2002-06-14 Chemical compounds
PCT/SE2003/000970 WO2003106420A1 (en) 2002-06-14 2003-06-10 2,5-disubstituted 3-mercaptopentanoic acid

Publications (1)

Publication Number Publication Date
NO20045051L true NO20045051L (no) 2005-01-13

Family

ID=20288202

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045051A NO20045051L (no) 2002-06-14 2004-11-19 2,5-disubstituerte 3-mercaptopentansyre

Country Status (29)

Country Link
US (1) US7572817B2 (no)
EP (1) EP1532111B1 (no)
JP (1) JP2005533064A (no)
KR (1) KR20050010051A (no)
CN (1) CN100415719C (no)
AR (1) AR040240A1 (no)
AT (1) ATE369342T1 (no)
AU (1) AU2003241260B2 (no)
BR (1) BR0311384A (no)
CA (1) CA2488606A1 (no)
CY (1) CY1107753T1 (no)
DE (1) DE60315471T2 (no)
DK (1) DK1532111T3 (no)
ES (1) ES2289297T3 (no)
HK (1) HK1077296A1 (no)
IS (1) IS7609A (no)
MX (1) MXPA04012604A (no)
MY (1) MY160429A (no)
NO (1) NO20045051L (no)
NZ (1) NZ536814A (no)
PL (1) PL373883A1 (no)
PT (1) PT1532111E (no)
RU (1) RU2365583C2 (no)
SA (1) SA03240142B1 (no)
SE (1) SE0201837D0 (no)
TW (1) TW200401766A (no)
UA (1) UA78042C2 (no)
WO (1) WO2003106420A1 (no)
ZA (1) ZA200409955B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
WO2006101740A2 (en) * 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
WO2010050525A1 (ja) 2008-10-29 2010-05-06 大正製薬株式会社 TAFIa阻害活性を有する化合物
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
KR102309654B1 (ko) 2013-04-18 2021-10-08 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
US9834527B2 (en) 2013-06-10 2017-12-05 Sanofi Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4687500A (en) * 1999-04-29 2000-11-17 Allergan Sales, Inc. Thromboxane ligands without blood clotting side effects
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds

Also Published As

Publication number Publication date
MXPA04012604A (es) 2005-03-23
KR20050010051A (ko) 2005-01-26
EP1532111B1 (en) 2007-08-08
JP2005533064A (ja) 2005-11-04
SE0201837D0 (sv) 2002-06-14
WO2003106420A1 (en) 2003-12-24
NZ536814A (en) 2006-11-30
CN1662504A (zh) 2005-08-31
UA78042C2 (en) 2007-02-15
DE60315471D1 (de) 2007-09-20
PT1532111E (pt) 2007-09-25
AU2003241260A1 (en) 2003-12-31
BR0311384A (pt) 2005-03-15
ATE369342T1 (de) 2007-08-15
DK1532111T3 (da) 2007-10-22
CY1107753T1 (el) 2013-04-18
ZA200409955B (en) 2006-08-30
IS7609A (is) 2004-12-22
CA2488606A1 (en) 2003-12-24
AR040240A1 (es) 2005-03-23
SA03240142B1 (ar) 2007-07-31
PL373883A1 (en) 2005-09-19
RU2004134563A (ru) 2005-07-20
TW200401766A (en) 2004-02-01
DE60315471T2 (de) 2008-04-24
US7572817B2 (en) 2009-08-11
ES2289297T3 (es) 2008-02-01
HK1077296A1 (en) 2006-02-10
US20050176780A1 (en) 2005-08-11
MY160429A (en) 2017-03-15
CN100415719C (zh) 2008-09-03
AU2003241260B2 (en) 2007-04-26
RU2365583C2 (ru) 2009-08-27
EP1532111A1 (en) 2005-05-25

Similar Documents

Publication Publication Date Title
NO20051265L (no) Anvendelse av og noen nye imidazopyridiner
CA2223403A1 (en) Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n-¬(aminoiminomethyl)phenylalkyl|-azaheterocyclylamide compounds
IL166412A0 (en) Novel use of benzothiazole derivatives
SE9901573D0 (sv) New compounds
NO20041041L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
NO20051962L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
WO2004037807A3 (en) Medicinal arylethanolamine compounds
NO20055565L (no) Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO)
NO20051010L (no) Triazolderivater som transformerende vekst faktor (TGF) inhibitorer
WO2001039759A3 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
NO331002B1 (no) Tioxantinderivater og farmasoytiske preparater med tioxantinderivater
CY1107753T1 (el) 2,5-δισυποκατεστημενο 3-μερκαπτοπεντανοϊκο οξυ
NO20044571L (no) Isokinolinderivater
US3922340A (en) Pharmaceutical compositions for treating lung diseases
SE9901572D0 (sv) New compounds
NO20054360L (no) Nye oxazolderivater, deres fremstilling og anvendelse som farmasotiske preparater
MXPA02001740A (es) Uso de bis-sulfonamidas para producir medicinas para la profilaxis o tratamiento de hiperlipidemia.
HUT48588A (en) Process for production of derivatives of 4-/aroil-amin/-piperidin buthan amid and medical preparatives containg these substances
SE0103272D0 (sv) Chemical compounds
MA27157A1 (fr) Methode de traitement d'affections osseuses.
NO20045223L (no) Orto-substituerte benzosyrederivater for behandling av insulinresistens
AU2001260695A1 (en) Malto-oligosaccharide derivatives and use thereof
MXPA01007833A (es) Metodo para prevenir o reducir eventos cardiovasculares asociados con intervencion de la arteria coronaria.
JPS6144818A (ja) 抗動脈硬化症剤

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application